Thursday 7 May, 2026
Introduction/Objectives Antibody-drug conjugates (ADCs) present unique pharmacokinetic challenges arising from the interplay between antibody disposition, payload deconjugation, and the fate…
Read moreOral: Drug/Disease Modelling - Oncology
Model-Based Quantification of Soluble CEACAM5 Impact on the Pharmacokinetics of A T-Cell Bispecific Antibody to Inform Clinical Decisions
Thursday 7 May, 2026
INTRODUCTION T cell–redirecting bispecific antibodies (TCBs) targeting CEACAM5 are being developed as a therapeutic in colorectal cancer (CRC) [1]. CEACAM5…
Read moreIntegration of mechanistic pharmacokinetic models with gene regulatory networks for early detection of resistance in Chronic Lymphocytic Leukaemia
Thursday 7 May, 2026
Background: Chronic Lymphocytic Leukaemia (CLL) exhibits heterogeneous therapeutic responses, with a substantial subset of patients developing resistance to standard treatments….
Read morePrognostic value of organ-specific tumor dynamics on overall survival across nine cancer types: a two-stage individual patient data meta-analysis of multilevel joint models
Thursday 7 May, 2026
Objectives: Overall survival (OS) is the main endpoint in oncology randomized clinical trials (RCTs), yet its late observation limits the…
Read moreMechanistic modelling of tumor kinetics coupled with biomarker dynamics for survival prediction in non-small cell lung cancer patients
Thursday 16 October, 2025
Objectives: Simple blood markers derived from routine hematology or biochemistry have been reported to be prognostic factors of overall survival (OS) in cancer patients [1,2]. However, most studies only use baseline (BSL) values. The only longitudinal biomarker that has been extensively used and modeled to date is tumor size kinetics…
Read moreThe combined use of propensity score matching and a joint tumor growth dynamics (TGD) – Overall Survival (OS) model to benchmark the efficacy of new treatments for advanced renal cell carcinoma (RCC)
Thursday 16 October, 2025
Objectives: Modeling tumor growth dynamics in different tumor types and under various therapeutic interventions has been an active area of…
Read moreDo tree-based machine learning methods outperform Cox regression for progression-free survival prediction in mobocertinib treated lung cancer patients?
Thursday 16 October, 2025
Objectives: Prediction of survival curves, overall survival (OS) and progression-free survival (PFS), based on pre-trained models could help to refine…
Read moreOptimizing Molecule Design for Bispecific Antibodies in Immuno-Oncology: A Case Study with FAP-4-1BBL
Thursday 16 October, 2025
Objectives: FAP-4-1BBL is a T-cell bispecific antibody exerting 4-1BB costimulation only while simultaneously bound to the Fibroblast Activation Protein (FAP)…
Read moreTarget-response relationship of bevacizumab may be more relevant than exposure-response – a target-mediated drug disposition (TMDD) model
Thursday 16 October, 2025
Introduction: Bevacizumab (BV), an anti-angiogenic monoclonal antibody targeting vascular endothelial growth factor (VEGF), has been approved for the treatment of metastatic…
Read moreJoint modelling of individual target lesions and survival to characterize the variability in the response to immunotherapy versus chemotherapy in advanced bladder cancer
Thursday 16 October, 2025
Context: In oncology, a common marker of tumor burden is the Sum of Longest Diameters (SLD) of target lesions, and…
Read more